Literature DB >> 9420048

Mechanisms of fluoroquinolone resistance in genetically related strains of Staphylococcus aureus.

G W Kaatz1, S M Seo.   

Abstract

Fluoroquinolone resistance in Staphylococcus aureus results from amino acid substitutions at particular locations in the DNA gyrase A and B subunits as well as in the topoisomerase IV A subunit and from NorA-mediated efflux. More than one resistance mechanism may be present in a single strain. Fluoroquinolone-resistant derivatives of SA-1199, a methicillin-susceptible S. aureus strain, were selected in vivo or in vitro, and their mechanisms of fluoroquinolone resistance were identified. We found that many of the resistance mechanisms described above can develop in derivatives of a single parent strain, either singly or in combination, and can arise in a single step. Variances in MICs for strains with the same apparent resistance mechanisms likely are due to the presence of new or undetected but established means of fluoroquinolone resistance. NorA-mediated resistance can occur in the apparent absence of topoisomerase mutations and in some strains may be the result of a promoter region mutation causing increased expression of norA. However, increased expression of norA can occur independently of this mutation, suggesting that a regulatory locus for this gene exists elsewhere on the chromosome.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9420048      PMCID: PMC164198     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Detection of gyrA gene mutations associated with ciprofloxacin resistance in methicillin-resistant Staphylococcus aureus: analysis by polymerase chain reaction and automated direct DNA sequencing.

Authors:  J J Goswitz; K E Willard; C E Fasching; L R Peterson
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

Review 2.  Genetic systems in staphylococci.

Authors:  R P Novick
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

3.  In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.

Authors:  G M Eliopoulos; K Klimm; C T Eliopoulos; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

4.  Mutants of the Bacillus subtilis multidrug transporter Bmr with altered sensitivity to the antihypertensive alkaloid reserpine.

Authors:  M Ahmed; C M Borsch; A A Neyfakh; S Schuldiner
Journal:  J Biol Chem       Date:  1993-05-25       Impact factor: 5.157

5.  DNA gyrase subunit stoichiometry and the covalent attachment of subunit A to DNA during DNA cleavage.

Authors:  A Sugino; N P Higgins; N R Cozzarelli
Journal:  Nucleic Acids Res       Date:  1980-09-11       Impact factor: 16.971

6.  DNA gyrase gyrA mutations in ciprofloxacin-resistant strains of Staphylococcus aureus: close similarity with quinolone resistance mutations in Escherichia coli.

Authors:  S Sreedharan; M Oram; B Jensen; L R Peterson; L M Fisher
Journal:  J Bacteriol       Date:  1990-12       Impact factor: 3.490

7.  Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter.

Authors:  A A Neyfakh; C M Borsch; G W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

8.  CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; K C Lamp; E M Bailey; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

9.  Mechanisms of fluoroquinolone resistance in Staphylococcus aureus.

Authors:  G W Kaatz; S M Seo; C A Ruble
Journal:  J Infect Dis       Date:  1991-05       Impact factor: 5.226

10.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

View more
  33 in total

1.  Introduction of a norA promoter region mutation into the chromosome of a fluoroquinolone-susceptible strain of Staphylococcus aureus using plasmid integration.

Authors:  G W Kaatz; S M Seo; T J Foster
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

2.  Association of alterations in ParC and GyrA proteins with resistance of clinical isolates of Enterococcus faecium to nine different fluoroquinolones.

Authors:  S Brisse; A C Fluit; U Wagner; P Heisig; D Milatovic; J Verhoef; S Scheuring; K Köhrer; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

3.  A mutation in the 5' untranslated region increases stability of norA mRNA, encoding a multidrug resistance transporter of Staphylococcus aureus.

Authors:  B Fournier; Q C Truong-Bolduc; X Zhang; D C Hooper
Journal:  J Bacteriol       Date:  2001-04       Impact factor: 3.490

Review 4.  Efflux-mediated resistance to fluoroquinolones in gram-positive bacteria and the mycobacteria.

Authors:  K Poole
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

5.  Novel ciprofloxacin-resistant, nalidixic acid-susceptible mutant of Staphylococcus aureus.

Authors:  Laura J V Piddock; Yu Fang Jin; Mark A Webber; Martin J Everett
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

Review 6.  Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria.

Authors:  Laura J V Piddock
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

7.  Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.

Authors:  Céline Vidaillac; Jean Guillon; Corinne Arpin; Isabelle Forfar-Bares; Boubakar B Ba; Jean Grellet; Stéphane Moreau; Daniel-Henri Caignard; Christian Jarry; Claudine Quentin
Journal:  Antimicrob Agents Chemother       Date:  2006-11-13       Impact factor: 5.191

8.  Efflux-related resistance to norfloxacin, dyes, and biocides in bloodstream isolates of Staphylococcus aureus.

Authors:  Carmen E DeMarco; Laurel A Cushing; Emmanuel Frempong-Manso; Susan M Seo; Tinevimbo A A Jaravaza; Glenn W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

9.  Accumulation of 99mTc-ciprofloxacin in Staphylococcus aureus and Pseudomonas aeruginosa.

Authors:  J M Sierra; D Rodriguez-Puig; A Soriano; J Mensa; C Piera; J Vila
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191

10.  The Role of Fluoroquinolones in the Treatment of Skin and Soft Tissue Infection.

Authors:  Md Rabiul Alam; Ellie Hershberger; Marcus J. Zervos
Journal:  Curr Infect Dis Rep       Date:  2002-10       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.